• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Sanuwave trial board wants more data

Sanuwave trial board wants more data

May 8, 2015 By Brad Perriello

Sanuwave trial board wants more data

Sanuwave Health (OTC:SNWV) said the oversight board for a clinical trial of its DermaPace diabetic foot ulcer treatment wants more data after determining that the trial is unlikely to meet its primary endpoint.

The Phase III trial’s primary efficacy endpoint is the rate of 100% complete wound closure at 12 weeks, compared with safety data and a sham control cohort, Sanuwave said.

An interim analysis by the trial’s independent Data Monitoring Committee found that if the trend holds the endpoint "will likely not be met at the next predefined analysis point of 170 patients," the company said. No safety issues were found by the DMC. The board now wants a look at the 24-week trial’s 20-week data because "the DMC noted the company had positive results at the 20-week endpoint in the 1st study of 206 patients completed in 2011," Sanuwave said.

That could mean either a halt for the trial so it can be used to back a pre-market approval application with the FDA late this year, or a continuation of the trial, the company said, noting that it’s "actively working" with the federal safety bureau to determine which course to take.

Back in 2011 the FDA sent Sanuwave a "major deficiency" letter and asked the company to run another trial for DermaPace, an extra-corporeal shock wave technology. The company launched the 2nd trial more than 3 years ago.

"We look forward to interactions with the FDA on enhancements to our rigorous study design. The DermaPace, with its novel biologic regenerative effects, holds promise to heal diabetic foot ulcers and increase limb preservation, thus improving quality of life for these patients and their families and significantly easing the economic burden on an overwhelmed healthcare system that cares for these patients," chairman Kevin Richardson II said in prepared remarks.

Filed Under: Food & Drug Administration (FDA), News Well Tagged With: Clinical Trials, SANUWAVE Health Inc., Wound Therapy

More recent news

  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system
  • EndoQuest Robotics completes first cases in pivotal surgical robot trial
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Intuitive Surgical is making a CEO change
  • GE HealthCare launches AI-based 3D reconstruction solution

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy